<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03662620</url>
  </required_header>
  <id_info>
    <org_study_id>YH22162-103</org_study_id>
    <nct_id>NCT03662620</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, open label, single-dose, replicate crossover clinical trial to
      compare the safety and pharmacokinetics of YH22162 in healthy male volunteers.

      Hypothesis: Study drug and comparator drug are showing equal pharmacokinetics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In ARM1, 32 subjects will be assigned and the subjects will be administered &quot;comparator drug&quot;
      at Day1/Day43 and &quot;study drug&quot; at Day22/64.

      In ARM2, 32 subjects will be assigned and the subjects will be administered &quot;study drug&quot; at
      Day1/Day43 and &quot;comparator drug&quot; at Day22/64.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2018</start_date>
  <completion_date type="Actual">December 22, 2018</completion_date>
  <primary_completion_date type="Actual">December 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, open-label, single-dose, 2-treatment, 2-sequence, 4-period replicate crossover design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of Telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>0-168 hrs</time_frame>
    <description>AUClast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>0-168 hrs</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>0-168 hrs</time_frame>
    <description>AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>0-168 hrs</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Telmisartan/amlodipine/chlorthalidone</measure>
    <time_frame>0-168 hrs</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ARM1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In ARM1, 32 subjects will be assigned and the subjects will be administered &quot;comparator drug&quot; at Day1/Day43 and &quot;study drug&quot; at Day22/64.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In ARM2, 32 subjects will be assigned and the subjects will be administered &quot;study drug&quot; at Day1/Day43 and &quot;comparator drug&quot; at Day22/64.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg</intervention_name>
    <description>White colored oval three-layer tablet</description>
    <arm_group_label>ARM1</arm_group_label>
    <arm_group_label>ARM2</arm_group_label>
    <other_name>Study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg</intervention_name>
    <description>White and pink colored oval two-layer tablet</description>
    <arm_group_label>ARM1</arm_group_label>
    <arm_group_label>ARM2</arm_group_label>
    <other_name>Comparator drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male with body mass index(BMI) between 18.5 and 30 kg/m2

          -  Who has not suffered from clinically significant disease

          -  Provision of signed written informed consent

        Exclusion Criteria:

          -  History of and clinically significant disease

          -  Administration of other investigational products within 3 months prior to the first
             dosing

          -  Volunteers considered not eligible for the clinical trial by the investigator due to
             reasons including laboratory test results, ECGs, or vital signs
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mingul Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollanam-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

